All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View AML content recommended for you
FDA clears IO-202, a novel LILRB4 antibody, for investigation as a new drug in AML
On May 29, 2020, the United States Food & Drug Administration (FDA) cleared IO-202, an antibody targeting leukocyte immunoglobulin-like receptor B4 (LILRB4), for investigation as a new drug treatment for acute myeloid leukemia (AML) in patients with monocytic differentiation and chronic myelomonocytic leukemia (CMML).1
Key features1
IO-202:
- A first-in-class monoclonal antibody that blocks the signaling of LILRB4, an immune inhibitory receptor
- The first T cell activator for AML
- Known to activate T cell cytotoxicity against leukemia cells in preclinical studies and block tumor infiltration
Study Design1,2
- Phase I, multicenter, open-label, dose-escalation and dose expansion study, to determine the optimal dose of IO-202 in adult patients with AML with monocytic differentiation and in those with CMML
- Will assess IO-202 as a monotherapy or in combination with azacitidine
- For the dose escalation phase, dose cohorts will be treated with intravenous (IV) IO-202 monotherapy, in ascending doses every 2 weeks, followed by IO-202 every 2 weeks at the same dose in combination with IV or subcutaneous azacitidine, 75 mg/m2 for 7 days every 28 days
- For the expansion phase, IV IO-202 monotherapy will be given at the recommended phase II dose and frequency; combination therapy will consist of IV IO-202 every 2 weeks at the recommended phase II dose and frequency with IV or subcutaneous azacitidine, 75 mg/m2 for 7 days every 28 days
- Primary outcomes will evaluate the safety and tolerability of IO-202
- Secondary outcomes will evaluate pharmacokinetics, pharmacodynamics, and clinical activity of IO-202
Biomarkers assessment will also enable a mechanistic understanding of the clinical data and inform future trials.
References